StockData
Merck & Co., Inc. logo

Merck & Co., Inc. (MRK) operating KPIs

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)

Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%

Merck pharmaceutical Sales — United States share of Pharmaceutical revenue (%) (%)

Form 8-K Supplemental Table 3c / 3b (Pharmaceutical Geographic Sales)

QuarterlyAnnual
Latest, Q2 2026
59.8%
Period ended Jun 30, 2026
Change on a year earlier
+0.5 pts
59.3% in Q2 2025
History
40 quarters
Since Q1 2016
Sources
16
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedPharmaceutical Sales — United States share of Pharmaceutical revenue (%) (%)Year on yearSource
Q2 2026Jun 30, 202659.8%+0.5 ptsForm 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q1 2026Mar 31, 202659.3%+1.2 ptsForm 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q4 2025Dec 31, 202558.4%+3.4 ptsForm 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q3 2025Sep 30, 202560.8%+5.7 ptsForm 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q2 2025Jun 30, 202559.3%+7.9 ptsForm 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q1 2025Mar 31, 202558.1%+8.6 ptsForm 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q4 2024Dec 31, 202455.0%+4.0 ptsForm 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q3 2024Sep 30, 202455.1%+5.0 ptsForm 8-K (tm2529620d1_ex99-1.htm, filed 2025-10-30) ↗
Q2 2024Jun 30, 202451.4%+2.6 ptsForm 8-K (tm2529620d1_ex99-1.htm, filed 2025-10-30) ↗
Q1 2024Mar 31, 202449.5%+1.4 ptsForm 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q4 2023Dec 31, 202351.0%+2.8 ptsForm 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q3 2023Sep 30, 202350.1%-1.0 ptsForm 8-K (tm2426878d1_ex99-1.htm, filed 2024-10-31) ↗
Q2 2023Jun 30, 202348.8%+3.9 ptsForm 8-K (tm2426878d1_ex99-1.htm, filed 2024-10-31) ↗
Q1 2023Mar 31, 202348.1%+0.1 ptsForm 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q4 2022Dec 31, 202248.2%+0.1 ptsForm 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
Q3 2022Sep 30, 202251.1%+1.8 ptsForm 8-K (tm2328962d1_ex99-1.htm, filed 2023-10-26) ↗

Cite this data

StockData. (2026). Merck Pharmaceutical Sales — United States share of Pharmaceutical revenue (%) (%), quarterly Q1 2016–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/pharma_geo_us_share

See every metric in the Merck KPI table. Data updated Oct 26, 2026.